Klaria Pharma Holding AB (publ.) Past Earnings Performance
Past criteria checks 0/6
Klaria Pharma Holding AB (publ.)'s earnings have been declining at an average annual rate of -12.1%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 20.9% per year.
Key information
-12.1%
Earnings growth rate
7.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -20.9% |
| Return on equity | -214.3% |
| Net Margin | 682.9% |
| Next Earnings Update | 21 Nov 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Klaria Pharma Holding AB (publ.) makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | -7 | -45 | 9 | -10 |
| 31 Mar 24 | -7 | -42 | 10 | -3 |
| 31 Dec 23 | 0 | -36 | 10 | 4 |
| 30 Sep 23 | 9 | -39 | 11 | 32 |
| 30 Jun 23 | 9 | -45 | 11 | 35 |
| 31 Mar 23 | 12 | -49 | 10 | 43 |
| 31 Dec 22 | 6 | -64 | 10 | 51 |
| 30 Sep 22 | 10 | -90 | 10 | 71 |
| 30 Jun 22 | 10 | -89 | 10 | 72 |
| 31 Mar 22 | 6 | -91 | 10 | 69 |
| 31 Dec 21 | 6 | -54 | 10 | 63 |
| 30 Sep 21 | 1 | -31 | 8 | 53 |
| 30 Jun 21 | 5 | -30 | 8 | 54 |
| 31 Mar 21 | 6 | -24 | 7 | 52 |
| 31 Dec 20 | 7 | -51 | 8 | 48 |
| 30 Sep 20 | 13 | -40 | 9 | 41 |
| 30 Jun 20 | 10 | -34 | 8 | 32 |
| 31 Mar 20 | 9 | -31 | 11 | 27 |
| 31 Dec 19 | 12 | -22 | 8 | 24 |
| 30 Sep 19 | 5 | -25 | 9 | 22 |
| 30 Jun 19 | 5 | -24 | 8 | 21 |
| 31 Mar 19 | 5 | -26 | 6 | 25 |
| 31 Dec 18 | 1 | -27 | 5 | 23 |
| 30 Sep 18 | 1 | -33 | 6 | 28 |
| 30 Jun 18 | 3 | -28 | 5 | 26 |
| 31 Mar 18 | 3 | -22 | 6 | 20 |
| 31 Dec 17 | 3 | -22 | 5 | 19 |
| 30 Sep 17 | 3 | -11 | 5 | 8 |
| 30 Jun 17 | 0 | -13 | 5 | 8 |
| 31 Mar 17 | 0 | -14 | 5 | 9 |
| 31 Dec 16 | 0 | -15 | 5 | 10 |
| 30 Sep 16 | 0 | -15 | 5 | 10 |
| 30 Jun 16 | 0 | -13 | 5 | 9 |
| 31 Mar 16 | 0 | -9 | 4 | 6 |
| 31 Dec 15 | 0 | -6 | 3 | 3 |
Quality Earnings: KLAR is currently unprofitable.
Growing Profit Margin: KLAR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KLAR is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare KLAR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KLAR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).
Return on Equity
High ROE: KLAR has a negative Return on Equity (-214.3%), as it is currently unprofitable.